Senior Scientist – Quantitative LC-MS Protein Bioanalysis
Amgen
Summary
Join the Pharmacokinetics & Drug Metabolism – Bioanalytical Sciences (PKDM-BA) group to advance Amgen's growing research portfolio. Develop and apply innovative, fit-for-purpose LC-MS-based bioanalytical assays for characterization of endogenous proteins, including distinct proteoforms and target-drug complexes.
Job description
Key Responsibilities
- Develop, optimize, and perform fit-for-purpose quantitative LC-MS assays to measure target proteins for the assessment of target abundance, target engagement, protein turnover, subcellular trafficking kinetics, protein-protein interactions, and etc.
- Design and implement innovative bioanalytical strategies and workflows that support mechanistic understanding of drug-target interactions, pathway modulation, pharmacodynamic responses, and biomarker kinetics.
- Apply quantitative mass spectrometry-based workflows to support studies in complex biological matrices, including plasma, tissue, and in vitro systems.
- Develop and adapt sample preparation, enrichment, and LC-MS workflows based on the intended biological question and assay requirements, balancing sensitivity, selectivity, robustness, and turnaround time.
- Independently troubleshoot assay development, sample preparation, data quality, and LC-MS instrument performance issues.
- Collaborate with cross-functional project teams to interpret bioanalytical data in the context of PK/PD, translational biomarkers, target biology, and mechanisms of action.
- Maintain accurate electronic laboratory notebook records, prepare technical reports, and communicate scientific results clearly to project teams and stakeholders.
Basic Qualifications
- Doctorate degree in Analytical Chemistry, Biochemistry, Pharmaceutical Sciences, Chemical Biology, Proteomics, or a related discipline with strong LC-MS training
- OR Master's degree and 4 years of relevant experience
- OR Bachelor's degree and 6 years of relevant experience
Preferred Qualifications
- Proven expertise in LC-MS method development and quantitative bioanalysis in complex biological matrices.
- Experience developing and applying quantitative assays for therapeutics, target engagement, target modulation, target dynamics, and biomarker biology.
- Hands-on experience with proteomics workflows, including peptide mapping, enzymatic digestion, protein-drug adduct identification, intact or subunit analysis, and quantitative protein or peptide assays.
- Experience with sample preparation techniques such as biological matrix processing, tissue homogenization, immunoaffinity capture, and other fit-for-purpose bioanalytical approaches.
- Experience with automated sample preparation platforms such as AssayMAP Bravo, Tecan, KingFisher, or related systems.
- Hands-on experience with LC-MS platforms, including high-flow, micro-flow, or nano-flow LC systems, triple quadrupole, Q-TOF, and Orbitrap systems.
- Ability to independently troubleshoot analytical methods, sample preparation workflows, data quality issues, and instrument performance.
- Strong communication, collaboration, and data interpretation skills, with the ability to present complex analytical results to multidisciplinary project teams.
Requirements
- Doctorate degree in Analytical Chemistry, Biochemistry, Pharmaceutical Sciences, Chemical Biology, Proteomics, or a related discipline with strong LC-MS training OR Master's degree and 4 years of relevant experience OR Bachelor's degree and 6 years of relevant experience
- Strong expertise in quantitative LC-MS bioanalysis
- Experience working with complex biological matrices
Company overview
Amgen Inc. is a leading American multinational biopharmaceutical company headquartered in Thousand Oaks, California, founded in 1980. As one of the world's largest independent biotechnology companies, Amgen specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on six key therapeutic areas: inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. Amgen's portfolio includes blockbuster drugs such as Enbrel for autoimmune diseases, Prolia and XGEVA for osteoporosis, Repatha for cholesterol management, Otezla for psoriasis, and Neulasta for chemotherapy-induced neutropenia. With approximately 28,000 employees worldwide, Amgen operates as a component of both the Dow Jones Industrial Average and Nasdaq-100 indices. The company maintains a robust research and development pipeline with numerous clinical programs across various stages, leveraging cutting-edge biotechnology and human genetic data to address some of the world's most challenging diseases. Amgen's manufacturing capabilities span multiple global locations, and it distributes products through pharmaceutical wholesale distributors and direct-to-consumer channels.